Art Ciociola is a Global Regulatory Affairs and Quality Assurance executive, specializing in ocular drug and device development with over 35 years of pharmaceutical drug development experience, who has played an instrumental role in the global approval of 18 new chemical entity drugs across multiple therapeutic areas, including ophthalmology, oncology, neurosciences, metabolic diseases, infectious diseases, and gastroenterology. The most recent global ophthalmology drug approvals, which Art has supported, include Beovu (brolucizumab), Luxturna (voretigene), Izba (travoprost), Simbrinza (brinzolamide/brimonidine), Pazeo (olopatadine), Xtoro (finafloxacin), Lotemax (loteprednol), and Besivance (besifloxacin). He also contributed to ophthalmic medical device approvals of the WaveLight Laser System, AcrySof ReSTOR intraocular lens, UltraSert IOL delivery device, AirOptix Dailies Total One contact lens, Systane Hydration, and Clear Care contact lens solutions.
Art has broad career experience in drug and medical device development that includes leading regulatory, quality, project management, technical operations, and clinical development groups at major pharmaceutical companies, including Novartis, Alcon, Bausch+Lomb, Abbott, Pfizer, and GSK.
Art is a thought leader and regular speaker at ophthalmology conferences, an author of over thirty-five peer-reviewed publications, an inventor of US Patents for gastrointestinal disorders, and a fellow of the American College of Gastroenterology.